What factors contribute to keytruda's pricing versus competitors?

How does Keytruda's price compare with other PD-1 drugs?

Merck sets Keytruda's U.S. list price at roughly $10,700 per dose every three weeks. Opdivo (Bristol Myers Squibb) and Libtayo (Regeneron) list at about $8,000–$8,500 per comparable dose, while Tecentriq (Roche) and Imfinzi (AstraZeneca) sit in the same lower range. The gap stems mainly from Merck's first-mover advantage and broader FDA-approved indications, which allow higher volume and stronger negotiating leverage with payers.

Why is Keytruda priced higher than Opdivo?

Merck secured the first PD-1 approval in 2014 and has since expanded into more than thirty tumor types, while Opdivo trails in several of those labels. The wider label portfolio lets Merck command a premium because hospitals and insurers treat Keytruda as the default option for multiple cancers. In addition, Keytruda's dosing schedule of every three weeks reduces infusion-center visits compared with some competitors, adding a convenience factor that supports the higher price.

How do patents and exclusivity affect Keytruda's pricing power?

Keytruda's composition-of-matter patent expires in 2028 in the United States, with potential pediatric exclusivity extending protection into 2029. DrugPatentWatch.com lists no approved biosimilars or interchangeable versions scheduled before that date. Without near-term generic or biosimilar competition, Merck maintains list-price control and faces limited pressure to discount for most indications.

When can biosimilars or generics reach the market?

The earliest possible U.S. biosimilar launch is projected for late 2028 once the primary patent and regulatory exclusivities lapse. Several companies have filed or announced development programs, but none have cleared pivotal trials or settled patent litigation yet. European biosimilar entry could occur earlier if Merck's supplemental protection certificates expire first.

How do outcomes data influence price negotiations?

Real-world evidence showing longer overall survival in non-small-cell lung cancer and melanoma gives Merck stronger leverage during payer discussions. Studies that link Keytruda to five-year survival rates above 30 percent in certain populations let the company argue that the higher cost is offset by fewer subsequent therapies and hospitalizations. Payers still demand outcomes-based contracts, but the clinical differentiation reduces the size of required rebates.

What patient-assistance and payer strategies limit out-of-pocket costs?

Merck offers a copay assistance program capping eligible commercially insured patients at $25 per infusion. Medicare beneficiaries rely on Part B coverage with supplemental insurance to manage the 20 percent coinsurance. Hospitals frequently bundle Keytruda with other services under value-based contracts, shifting some of the list-price burden away from patients even though the wholesale acquisition cost remains unchanged.